2024
WHO global research priorities for antimicrobial resistance in human health
Bertagnolio S, Dobreva Z, Centner C, Olaru I, Donà D, Burzo S, Huttner B, Chaillon A, Gebreselassie N, Wi T, Hasso-Agopsowicz M, Allegranzi B, Sati H, Ivanovska V, Kothari K, Balkhy H, Cassini A, Hamers R, Van Weezenbeek K, Collaborators W, Aanensen D, Alanio A, Alastruey-Izquierdo A, Alemayehu T, Al-Hasan M, Allegaert K, Al-Maani A, Al-Salman J, Alshukairi A, Amir A, Applegate T, Araj G, Villalobos M, Årdal C, Ashiru-Oredope D, Ashley E, Babin F, Bachmann L, Bachmann T, Baker K, Balasegaram M, Bamford C, Baquero F, Barcelona L, Bassat Q, Bassetti M, Basu S, Beardsley J, Vásquez G, Berkley J, Bhatnagar A, Bielicki J, Bines J, Bongomin F, Bonomo R, Bradley J, Bradshaw C, Brett A, Brink A, Brown C, Brown J, Buising K, Carson C, Carvalho A, Castagnola E, Cavaleri M, Cecchini M, Chabala C, Chaisson R, Chakrabarti A, Chandler C, Chandy S, Charani E, Chen L, Chiara F, Chowdhary A, Chua A, Chuki P, Chun D, Churchyard G, Cirillo D, Clack L, Coffin S, Cohn J, Cole M, Conly J, Cooper B, Corso A, Cosgrove S, Cox H, Daley C, Darboe S, Darton T, Davies G, de Egea V, Dedeić-Ljubović A, Deeves M, Denkinger C, Dillon J, Dramowski A, Eley B, Esposito S, Essack S, Farida H, Farooqi J, Feasey N, Ferreyra C, Fifer H, Finlayson H, Frick M, Gales A, Galli L, Gandra S, Gerber J, Giske C, Gordon B, Govender N, Guessennd N, Guindo I, Gurbanova E, Gwee A, Hagen F, Harbarth S, Haze J, Heim J, Hendriksen R, Heyderman R, Holt K, Hönigl M, Hook E, Hope W, Hopkins H, Hughes G, Ismail G, Issack M, Jacobs J, Jasovský D, Jehan F, Pearson A, Jones M, Joshi M, Kapil A, Kariuki S, Karkey A, Kearns G, Keddy K, Khanna N, Kitamura A, Kolho K, Kontoyiannis D, Kotwani A, Kozlov R, Kranzer K, Kularatne R, Lahra M, Langford B, Laniado-Laborin R, Larsson J, Lass-Flörl C, Le Doare K, Lee H, Lessa F, Levin A, Limmathurotsakul D, Lincopan N, Vecchio A, Lodha R, Loeb M, Longtin Y, Lye D, Mahmud A, Manaia C, Manderson L, Mareković I, Marimuthu K, Martin I, Mashe T, Mei Z, Meis J, De Melo F, Mendelson M, Miranda A, Moore D, Morel C, Moremi N, Moro M, Moussy F, Mshana S, Mueller A, Ndow F, Nicol M, Nunn A, Obaro S, Obiero C, Okeke I, Okomo U, Okwor T, Oladele R, Omulo S, Ondoa P, de Canese J, Ostrosky-Zeichner L, Padoveze M, Pai M, Park B, Parkhill J, Parry C, Peeling R, Peixe L, Perovic O, Pettigrew M, Principi N, Pulcini C, Puspandari N, Rawson T, Reddy D, Reddy K, Redner P, Tudela J, Rodríguez-Baño J, Van Katwyk S, Roilides E, Rollier C, Rollock L, Ronat J, Ruppe E, Sadarangani M, Salisbury D, Salou M, Samison L, Sanguinetti M, Sartelli M, Schellack N, Schouten J, Schwaber M, Seni J, Senok A, Shafer W, Shakoor S, Sheppard D, Shin J, Sia S, Sievert D, Singh I, Singla R, Skov R, Soge O, Sprute R, Srinivasan A, Srinivasan S, Sundsfjord A, Tacconelli E, Tahseen S, Tangcharoensathien V, Tängdén T, Thursky K, Thwaites G, de Souza Peral R, Tong D, Tootla H, Tsioutis C, Turner K, Turner P, Omar S, van de Sande W, van den Hof S, van Doorn R, Veeraraghavan B, Verweij P, Wahyuningsih R, Wang H, Warris A, Weinstock H, Wesangula E, Whiley D, White P, Williams P, Xiao Y, Moscoso M, Yang H, Yoshida S, Yu Y, Żabicka D, Zignol M. WHO global research priorities for antimicrobial resistance in human health. The Lancet Microbe 2024, 100902. PMID: 39146948, DOI: 10.1016/s2666-5247(24)00134-4.Peer-Reviewed Original ResearchAntimicrobial resistanceTreatment of antimicrobial-resistant infectionsConsequences of antimicrobial resistanceAntimicrobial resistance epidemiologyAntimicrobial-resistant infectionsDrug-resistant pathogensAntimicrobial resistance dynamicsResearch prioritiesComprehensive scoping reviewGeneration of evidenceGlobal research prioritiesScoping reviewWHOKnowledge gapsExpert inputResearch agendaHealthBurdenPathogensFungal pathogensPolicy translationTuberculosisDiagnosisInfectionParticipant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021
Kwon J, Pelletiers W, Peña J, van Duin D, Ledbetter L, Baum K, Ruffin F, Knisely J, Bizzell E, Fowler V, Chambers H, Pettigrew M. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021. Clinical Infectious Diseases 2024, 79: 141-147. PMID: 38306502, PMCID: PMC11259209, DOI: 10.1093/cid/ciae049.Peer-Reviewed Original ResearchMethicillin-resistant S. aureusRandomized controlled trialsPhase 2/3 trialsPhase 4 trialIncidence of methicillin-resistant S. aureusTreat Staphylococcus aureus infectionsStaphylococcus aureus infectionStandard of carePercentage of study participantsIncidence ratiosClinical trialsEthnicity of participantsControlled trialsStandardized reporting methodsBlack participantsStudy sizeInfectionDisease populationTrialsStudy participantsAntibacterial agentsIncreased recruitmentIndustry sponsorshipEthnicity dataSex
2023
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review
Doernberg S, Arias C, Altman D, Babiker A, Boucher H, Creech C, Cosgrove S, Evans S, Fowler V, Fritz S, Hamasaki T, Kelly B, Leal S, Liu C, Lodise T, Miller L, Munita J, Murray B, Pettigrew M, Ruffin F, Scheetz M, Shopsin B, Tran T, Turner N, Williams D, Zaharoff S, Holland T, Patel R, King H, Kinamon T, Dai W, Geres H, Deckard N, Schuler C, Bunn I, Sharma S, Wickward C, Waller J, Wilson H, Mehigan M, Ghazaryan V, Raterman E, Samuel T, Lee M. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. Clinical Infectious Diseases 2023, 77: s295-s304. PMID: 37843115, PMCID: PMC10578051, DOI: 10.1093/cid/ciad565.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupMRSA bloodstream infectionsMethicillin-resistant Staphylococcus aureusBloodstream infectionsClinical trialsPediatric community-acquired pneumoniaInfection researchEnterococcal bloodstream infectionsOptimal vancomycin dosingOptimization of dosingRole of dalbavancinCommunity-acquired pneumoniaShort-course therapyInterventional clinical trialsVancomycin-resistant enterococciVancomycin dosingPositive infectionsNovel agentsLife measuresTreat infectionsClinical practiceNarrative reviewInfectionPositive bacteriaStaphylococcus aureus
2021
Antibacterial Resistance Leadership Group 2.0: Back to Business
Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D, Tsalik EL, Holland TL, Pettigrew MM, Tamma PD, Hodges KR, Souli M, Fowler VG. Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical Infectious Diseases 2021, 73: 730-739. PMID: 33588438, PMCID: PMC8366825, DOI: 10.1093/cid/ciab141.Peer-Reviewed Original Research
2019
Non-typeable Haemophilus influenzae isolates from patients with chronic obstructive pulmonary disease contain new phase-variable modA methyltransferase alleles controlling phasevarions
Atack JM, Murphy TF, Pettigrew MM, Seib KL, Jennings MP. Non-typeable Haemophilus influenzae isolates from patients with chronic obstructive pulmonary disease contain new phase-variable modA methyltransferase alleles controlling phasevarions. Scientific Reports 2019, 9: 15963. PMID: 31685916, PMCID: PMC6828955, DOI: 10.1038/s41598-019-52429-6.Peer-Reviewed Original ResearchConceptsNon-typeable Haemophilus influenzaeChronic obstructive pulmonary diseaseObstructive pulmonary diseaseMiddle ear infectionPulmonary diseaseEar infectionsNTHi strainsHaemophilus influenzaeExacerbation of COPDCOPDMiddle earPatientsAllele distributionInfectionInfluenzaeBacterial pathogensDiseaseMultiple allelic variantsAllelic variantsGene expressionAllelesEpigenetic mechanismsLarge panelExacerbationExpression
2018
Changes in IgA Protease Expression Are Conferred by Changes in Genomes during Persistent Infection by Nontypeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease
Gallo MC, Kirkham C, Eng S, Bebawee RS, Kong Y, Pettigrew MM, Tettelin H, Murphy TF. Changes in IgA Protease Expression Are Conferred by Changes in Genomes during Persistent Infection by Nontypeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Infection And Immunity 2018, 86: 10.1128/iai.00313-18. PMID: 29760213, PMCID: PMC6056860, DOI: 10.1128/iai.00313-18.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseasePersistent infectionPulmonary diseaseIgA proteaseProtease expressionNontypeable Haemophilus influenzaeAcute exacerbationLower airwaysRespiratory tractNTHi strainsHaemophilus influenzaeInfectionNTHiNatural infectionHuman pathobiontAltered expressionPatientsDiseasePersistent strainsExpressionCritical roleExacerbationAirwayInitial acquisition
2015
Expression of IgA Proteases by Haemophilus influenzae in the Respiratory Tract of Adults With Chronic Obstructive Pulmonary Disease
Murphy TF, Kirkham C, Jones MM, Sethi S, Kong Y, Pettigrew MM. Expression of IgA Proteases by Haemophilus influenzae in the Respiratory Tract of Adults With Chronic Obstructive Pulmonary Disease. The Journal Of Infectious Diseases 2015, 212: 1798-1805. PMID: 25995193, PMCID: PMC4633762, DOI: 10.1093/infdis/jiv299.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseH. influenzaeIgA protease genePulmonary diseaseHuman airwaysHaemophilus influenzaeIgA proteaseH. influenzae infectionsHuman respiratory epithelial cellsHuman IgA1Respiratory epithelial cellsInfluenzae infectionRespiratory tractIgA protease activitySputum samplesClinical settingInfluenzaeEpithelial cellsInfectionAirwayIgA1 fragmentsDiseaseIgA1Protease geneStreptococcus pneumoniae biofilm formation and dispersion during colonization and disease
Chao Y, Marks LR, Pettigrew MM, Hakansson AP. Streptococcus pneumoniae biofilm formation and dispersion during colonization and disease. Frontiers In Cellular And Infection Microbiology 2015, 4: 194. PMID: 25629011, PMCID: PMC4292784, DOI: 10.3389/fcimb.2014.00194.Peer-Reviewed Original ResearchConceptsNasopharyngeal environmentConcomitant virus infectionPneumococcal biofilmsMiddle ear infectionRespiratory epithelial cellsMillions of infectionsPneumococcal biofilm formationPneumococcal diseaseEar infectionsSterile sitesInvasive diseasePneumococcal colonizationHigh prevalenceVirus infectionDisease processDistinct phenotypic propertiesMucosal surfacesStreptococcus pneumoniaeVaccine escapeHuman nasopharynxDiseaseEpithelial cellsInfectionPneumococciAntibiotic resistance
2014
Antibacterial Resistance Leadership Group: Open for Business
Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG. Antibacterial Resistance Leadership Group: Open for Business. Clinical Infectious Diseases 2014, 58: 1571-1576. PMID: 24610430, PMCID: PMC4017892, DOI: 10.1093/cid/ciu132.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupAntibacterial resistanceClinical research agendaPublic health threatClinical research opportunitiesInfection preventionClinical studiesAntimicrobial stewardshipClinical research proposalsInfectious diseasesClinical researchHealth threatNational InstituteInfectionMedical practiceHigh priority areasNegative bacteriaPositive bacteriaAllergyDiseasePrevention
2012
Controlling Antimicrobial Resistance through Targeted, Vaccine-Induced Replacement of Strains
Tekle YI, Nielsen KM, Liu J, Pettigrew MM, Meyers LA, Galvani AP, Townsend JP. Controlling Antimicrobial Resistance through Targeted, Vaccine-Induced Replacement of Strains. PLOS ONE 2012, 7: e50688. PMID: 23227198, PMCID: PMC3515573, DOI: 10.1371/journal.pone.0050688.Peer-Reviewed Original ResearchConceptsFirst clinical interventionImportant public health toolPan-resistant strainsInsufficient immune responsePublic health toolMulti-resistant strainsStaphylococcus aureus genotypesVaccine efficacyNosocomial outbreaksDrug treatmentImmune responseResistant serotypesFrequent reasonHypothetical vaccineVaccine developmentStrain replacementVaccineInfectious diseasesAureus genotypesClinical interventionsInfectionHealth toolsAntimicrobial resistanceIntervention strategiesSerotypesVirulence of Streptococcus pneumoniae serotype 6C in experimental otitis media
Sabharwal V, Figueira M, Pelton SI, Pettigrew MM. Virulence of Streptococcus pneumoniae serotype 6C in experimental otitis media. Microbes And Infection 2012, 14: 712-718. PMID: 22414497, PMCID: PMC3382049, DOI: 10.1016/j.micinf.2012.02.008.Peer-Reviewed Original ResearchConceptsAcute otitis mediaExperimental otitis mediaPneumococcal conjugate vaccineOtitis mediaSerotype 6CInvasive pneumococcal diseaseOverall carriage rateLow-density infectionsMiddle ear infectionStreptococcus pneumoniae serotype 6CReplacement serotypesPneumococcal diseaseVaccine serotypesConjugate vaccineNonvaccine serotypesCarriage rateEar infectionsNasopharyngeal colonizationChinchilla modelStreptococcus pneumoniaeHost defenseSerotypesDisease potentialInfectionDisease
2011
Multiple chlamydia infection among young women: comparing the role of individual- and neighbourhood-level measures of socioeconomic status
Biello KB, Pettigrew MM, Niccolai LM. Multiple chlamydia infection among young women: comparing the role of individual- and neighbourhood-level measures of socioeconomic status. Sexually Transmitted Infections 2011, 87: 560. PMID: 21940727, PMCID: PMC3438508, DOI: 10.1136/sextrans-2011-050185.Peer-Reviewed Original ResearchConceptsIndividual-level socioeconomic statusChlamydia diagnosisYoung womenSocioeconomic statusChlamydia infectionNeighborhood-level socioeconomic statusIndividual-level SESNeighborhood socioeconomic statusHigh burdenNeighborhood-level povertyMultiple infectionsSocioeconomic disparitiesDiagnosisNeighborhood-level measuresWomenInfectionHigh-poverty areasLow-poverty areasValid measureBurdenIndividual-level measuresStatusUseful measureIndividual-level variablesChlamydiaBehavioural sources of repeat Chlamydia trachomatis infections: importance of different sex partners
Niccolai LM, Livingston KA, Laufer AS, Pettigrew MM. Behavioural sources of repeat Chlamydia trachomatis infections: importance of different sex partners. Sexually Transmitted Infections 2011, 87: 248. PMID: 21212380, PMCID: PMC5438152, DOI: 10.1136/sti.2010.045484.Peer-Reviewed Original ResearchConceptsChlamydia trachomatis infectionRepeat infectionsNew sex partnerTrachomatis infectionSex partnersC. trachomatisRepeat Chlamydia trachomatis infectionsPopulation attributable risk percentageC. trachomatis infectionCumulative incidenceDifferent-sex partnersRisk percentageYounger ageInfectionBehavioral surveyBaselineDifferent genotypesTrachomatisWomenMolecular methodsGenotypesPatientsFollowIncidence
2009
Comparison of Sexual Partnership Characteristics and Associations with Inconsistent Condom Use among a Sample of Adolescents and Adult Women Diagnosed with Chlamydia trachomatis
Foulkes HB, Pettigrew MM, Livingston KA, Niccolai LM. Comparison of Sexual Partnership Characteristics and Associations with Inconsistent Condom Use among a Sample of Adolescents and Adult Women Diagnosed with Chlamydia trachomatis. Journal Of Women's Health 2009, 18: 393-399. PMID: 19245304, DOI: 10.1089/jwh.2008.0840.Peer-Reviewed Original ResearchConceptsInconsistent condom useCondom useSexual partnershipsPrevalent chlamydia infectionSexual partnership characteristicsPartner age differenceChlamydia infectionMain partnershipsChlamydia trachomatisAdult womenPrevention effortsSexual relationshipsAdolescent femalesPartnership durationFemale adolescentsPartnership characteristicsSample of adolescentsShort durationAdolescentsInfectionWomenDurationType of partner
2003
Molecular epidemiology of Streptococcus pneumoniae mediated otitis media.
McCoy S, Pettigrew M. Molecular epidemiology of Streptococcus pneumoniae mediated otitis media. Frontiers In Bioscience-Landmark 2003, 8: e87-93. PMID: 12456346, DOI: 10.2741/961.Peer-Reviewed Original Research